Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

Billionaire Stanley Druckenmiller's Duquesne Family Office has fully divested its Palantir Technologies stake over nine months, a move potentially driven by the AI firm's extreme valuation (P/S ~140) and broader AI bubble concerns, rather than solely profit-taking. Simultaneously, Druckenmiller has significantly increased his holdings in Teva Pharmaceutical Industries for four consecutive quarters, making it Duquesne's second-largest position. This pivot into Teva reflects the resolution of major litigation, the company's strategic shift towards higher-margin brand-name drugs, and its historically low valuation (forward P/E ~6), indicating a strategic shift from high-growth AI to a de-risked value opportunity.

Analysis

Analysis of 13F filings reveals a significant strategic rotation by Stanley Druckenmiller's Duquesne Family Office, pivoting away from high-valuation artificial intelligence and into a de-risked pharmaceutical turnaround story. Over a nine-month period ending in March 2025, the fund completely liquidated its position in Palantir (PLTR), a move likely motivated by more than simple profit-taking. The primary concern appears to be Palantir's extreme valuation, with its price-to-sales ratio reaching approximately 140, a level that significantly exceeds the 30-40 P/S ratios seen at the peak of the dot-com bubble and raises concerns about a potential AI sector correction. In stark contrast, Druckenmiller has aggressively accumulated a position in Teva Pharmaceutical (TEVA) over four consecutive quarters, making it the fund's second-largest holding. This investment thesis is underpinned by Teva's improved fundamentals, including the resolution of its major opioid litigation through a $4.25 billion settlement, a strategic shift toward higher-margin branded drugs like Austedo, and successful debt reduction. The valuation is compelling, with Teva trading at a forward price-to-earnings ratio of approximately 6, a deep discount compared to the broader market and a clear indicator of a value-oriented play.

Key Decisions for Investors

• Given Druckenmiller's complete divestment and the highlighted valuation risk, investors in Palantir should critically assess its price-to-sales ratio of ~140 and consider the potential for a sentiment shift or correction in the AI sector.
• The sustained, heavy accumulation of Teva by a prominent investor, combined with its litigation resolution and low forward P/E of ~6, suggests the stock warrants consideration as a value-oriented turnaround play in the pharmaceutical industry.
• This rotation from a high-multiple growth stock to a low-multiple value stock may signal a broader market theme; investors should review their own portfolio's balance between high-growth technology and fundamentally improving, lower-valuation sectors.
• Investors should monitor future 13F filings to track whether this institutional rotation continues, as such capital flows can act as a leading indicator for sector performance and risk appetite.